ESTRO 2024 - Abstract Book

S5904

RTT - Service evaluation, quality assurance and risk management

ESTRO 2024

stored on the local oncology network. This database has been recorded and archived since 2020 and is available for the radiotherapy on-treatment review team to refer to. The database also records the patient’s personal radiotherapy number (RTH) and a concise description of how the concern was resolved. An annotation of the resolution is then noted in the patient’s radiotherapy notes. This can only be accessed by those employed in the host department through the use of an appropriate username and password. This serves as the basis for the collection of data for this service evaluation. Purposeful sampling was then utilised to only include patients who had undergone 26Gy/5#/one week of whole breast radiotherapy. The data was then analysed to determine any key themes within the concerns of the patient. Further, the time (in days) between finishing treatment and the call to the RALS were plotted to establish a theme in the point at which patients are most likely in need of support. Finally, the data regarding any other intervention can be presented and can be evaluated against the symptoms that are reported to ascertain whether there was any correlation.

Results:

Between April 2020 and April 2023, 53 patients in total met the inclusion criteria for this study and called the RALS for support or advice following their treatment. A significant finding was that the most common side effects reported were regarding skin toxicity. Additionally, the most common time frame for calling post treatment was 2.7 weeks after finishing their radiotherapy treatment. The dataset showed a noteworthy number of patients mentioned that they had spoken to their GP for advice or intervention prior to calling RALS.

Conclusion:

The results of this service evaluation have demonstrated that patients who have undergone 26Gy/5#/1week radiotherapy to their whole breast are contacting the current RALS to discuss their side effects and for advice or support. The most common time frame for their call is around 2.7 weeks post treatment and their most reported side effect is their skin toxicity. Further, the time between finishing radiotherapy and calling the RALS could be hypothesised as an indicator of when side effects after treatment are at their worst and therefore when patients are calling for advice and support. The FAST-Forward trial results support this hypothesis. The results also show a proportion of this population are contacting their GP for support. Further investigation would be needed to establish how to most effectively utilise the Integrated Care System for this purpose. But more research is required in order to utilise both systems efficiently. This should then be communicated well to patients.

Keywords: Breast, Review, Follow-Up

1674

Digital Poster

Bladder and rectal dose accumulation for prostate radiotherapy agrees with planned dose goals

Djoeri Lipman, Tommi S Leijstra, Thirza E van Garderen, Rosalie R Docter, Rik Westendorp

Isala, Radiotherapy, Zwolle, Netherlands